Observational Research on Sodium Glucose Co-transporter-2 Inhibitors: A Real Breakthrough?

Overview

Journal Diabetes Obes Metab

Specialty Endocrinology

Date 2018 Jul 14

PMID 30003655

Citations 10

Authors

Emanuel Raschi

Elisabetta Poluzzi

Gian Paolo Fadini

Giulio Marchesini

Fabrizio De Ponti

Affiliations

Soon will be listed here.

Abstract

Sodium glucose co-transporter-2 inhibitors have attracted the interest of the scientific community following the results from dedicated cardiovascular outcome trials, which demonstrated remarkable reduction in all-cause mortality and other cardiovascular (CV) endpoints with empagliflozin and canagliflozin. These impressive results raised further expectations on real world data from large observational cohort studies. They were designed to address the possible existence of a class effect, and the uncertainty on whether this benefit can be extended from secondary to primary CV prevention of patients with type 2 diabetes. In this review, we collated data from existing observational studies (including the celebrated CVD-REAL cohorts) and critically appraised results and methodological issues with the aim of providing clinical insight, including unsettled aspects, and proposing a research agenda for future investigations.

Citing Articles

Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.

Fadini G, Longato E, Morieri M, Del Prato S, Avogaro A, Solini A Lancet Reg Health Eur. 2024; 38:100847.

PMID: 38328413 PMC: 10847023. DOI: 10.1016/j.lanepe.2024.100847.

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population.

Shen L, Yang H, Fang X, Huang H, Yao W, Chen D Diabetes Metab Syndr Obes. 2021; 14:1621-1630.

PMID: 33880048 PMC: 8053501. DOI: 10.2147/DMSO.S300494.

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.

Bonora B, Raschi E, Avogaro A, Fadini G Cardiovasc Diabetol. 2021; 20(1):39.

PMID: 33573667 PMC: 7879696. DOI: 10.1186/s12933-021-01243-4.

Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Scheen A Nat Rev Endocrinol. 2020; 16(10):556-577.

PMID: 32855502 DOI: 10.1038/s41574-020-0392-2.

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence.

Bonora B, Avogaro A, Fadini G Diabetes Metab Syndr Obes. 2020; 13:161-174.

PMID: 32021362 PMC: 6982447. DOI: 10.2147/DMSO.S233538.

References

Franklin J, Schneeweiss S . When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?. Clin Pharmacol Ther. 2017; 102(6):924-933. DOI: 10.1002/cpt.857. View

Suissa S . Response to Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10. Diabetes Care. 2018; 41(6):e109-e110. DOI: 10.2337/dci18-0015. View

Suissa S . Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?. Diabetes Care. 2017; 41(1):6-10. DOI: 10.2337/dc17-1223. View

Toulis K, Willis B, Marshall T, Kumarendran B, Gokhale K, Ghosh S . All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database. J Clin Endocrinol Metab. 2017; 102(5):1719-1725. DOI: 10.1210/jc.2016-3446. View

Kosiborod M, Birkeland K, Cavender M, Fu A, Wilding J, Khunti K . Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study. Diabetes Obes Metab. 2018; 20(8):1983-1987. PMC: 6055705. DOI: 10.1111/dom.13299. View

Faillie J . Pharmacological aspects of the safety of gliflozins. Pharmacol Res. 2016; 118:71-81. DOI: 10.1016/j.phrs.2016.07.001. View

Udell J, Yuan Z, Rush T, Sicignano N, Galitz M, Rosenthal N . Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real.... Circulation. 2017; 137(14):1450-1459. PMC: 5895161. DOI: 10.1161/CIRCULATIONAHA.117.031227. View

Fadini G, Sarangdhar M, Avogaro A . Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions. Diabetes Ther. 2018; 9(2):851-861. PMC: 6104265. DOI: 10.1007/s13300-018-0408-2. View

Perlman A, Heyman S, Matok I, Stokar J, Muszkat M, Szalat A . Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis. 2017; 27(12):1108-1113. DOI: 10.1016/j.numecd.2017.10.011. View

10.

Nystrom T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson J . Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10. Diabetes Care. 2018; 41(6):e104-e105. DOI: 10.2337/dc18-0339. View

11.

Patorno E, Patrick A, Garry E, Schneeweiss S, Gillet V, Bartels D . Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations. Diabetologia. 2014; 57(11):2237-50. DOI: 10.1007/s00125-014-3364-z. View

12.

Persson F, Nystrom T, Jorgensen M, Carstensen B, Gulseth H, Thuresson M . Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab. 2017; 20(2):344-351. PMC: 5811811. DOI: 10.1111/dom.13077. View

13.

Scheen A . Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circ Res. 2018; 122(10):1439-1459. PMC: 5959222. DOI: 10.1161/CIRCRESAHA.117.311588. View

14.

Goyat R, Rai P, Chang J, Ponte C, Tan X . Cardiovascular Mortality of Oral Antidiabetic Drugs Approved Before and After the 2008 US FDA Guidance for Industry: A Systemic Review and Meta-Analysis. Clin Drug Investig. 2018; 38(6):491-501. PMC: 5953843. DOI: 10.1007/s40261-018-0639-z. View

15.

Roberto G, Leal I, Sattar N, Loomis A, Avillach P, Egger P . Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project. PLoS One. 2016; 11(8):e0160648. PMC: 5006970. DOI: 10.1371/journal.pone.0160648. View

16.

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View

17.

Zheng S, Roddick A, Aghar-Jaffar R, Shun-Shin M, Francis D, Oliver N . Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA. 2018; 319(15):1580-1591. PMC: 5933330. DOI: 10.1001/jama.2018.3024. View

18.

Khouri C, Cracowski J, Roustit M . SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?. Diabetes Obes Metab. 2018; 20(6):1531-1534. DOI: 10.1111/dom.13255. View

19.

Elze M, Gregson J, Baber U, Williamson E, Sartori S, Mehran R . Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. J Am Coll Cardiol. 2017; 69(3):345-357. DOI: 10.1016/j.jacc.2016.10.060. View

20.

Ioannidis J . The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses. Milbank Q. 2016; 94(3):485-514. PMC: 5020151. DOI: 10.1111/1468-0009.12210. View